Literature DB >> 20959641

Factors derived from preeclamptic placentas perturb polarity protein PARD-3 expression and distribution in endothelial cells.

Juan Zhao1, Yang Gu, Ruping Fan, Lynn J Groome, Yuping Wang.   

Abstract

OBJECTIVE: This study aimed to examine (1) whether polarity protein partitioning defective-3 (PARD-3) was expressed in endothelial cells (ECs) and contributed to endothelial barrier integrity and (2) whether altered PARD-3 expression and distribution were associated with disturbed endothelial junction protein VE-cadherin expression induced by factors derived from preeclamptic (PE) placentas.
METHODS: PARD-3 and VE-cadherin expressions were examined by immunofluorescent staining and Western blot in confluent ECs and in ECs treated with normal and PE placental conditioned medium (CM). Protein-protein interactions between PARD-3/VE-cadherin, PARD-3/ atypical protein kinase C (aPKCλ), and VE-cadherin/aPKCλ were examined by immuno-precipitation and immunobloting.
RESULTS: Similar to VE-cadherin, PARD-3 is localized at the cell contacts in control ECs. Both PARD-3 and VE-cadherin expressions were markedly reduced in cells treated with PE-CM for 2h, but not in cells treated with normal-CM compared to non-treated controls. Cytosol staining of VE-cadherin and PARD-3 was pronounced in cells after 24h treatment with PE-CM. PARD-3/VE-cadherin and PARD-3/aPKCλ complexes were detected in PE-CM treated cells, but not in untreated control cells and in cells after recovery. In contrast, VE-cadherin/aPKCλ complex was detected in control cells and in cells after recovery, but not in PE-CM treated cells.
CONCLUSIONS: Polarity protein PARD-3 is localized at cell contacts. Factors-derived from PE placentas not only interrupt junction protein VE-cadherin distribution, but also perturb polarity protein PARD-3 expression and distribution in ECs. The results of PARD-3/VE-cadherin and PARD-3/aPKCλ complexes formation in cells treated with placental CM suggest that factors-derived from placenta could interfere both junction protein and polarity protein functions in ECs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959641      PMCID: PMC3062264          DOI: 10.1177/1933719110382920

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  18 in total

1.  The cell polarity protein ASIP/PAR-3 directly associates with junctional adhesion molecule (JAM).

Authors:  K Ebnet; A Suzuki; Y Horikoshi; T Hirose; M K Meyer Zu Brickwedde; S Ohno; D Vestweber
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

2.  A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity.

Authors:  D Lin; A S Edwards; J P Fawcett; G Mbamalu; J D Scott; T Pawson
Journal:  Nat Cell Biol       Date:  2000-08       Impact factor: 28.824

3.  The cell-polarity protein Par6 links Par3 and atypical protein kinase C to Cdc42.

Authors:  G Joberty; C Petersen; L Gao; I G Macara
Journal:  Nat Cell Biol       Date:  2000-08       Impact factor: 28.824

4.  aPKC kinase activity is required for the asymmetric differentiation of the premature junctional complex during epithelial cell polarization.

Authors:  Atsushi Suzuki; Chikako Ishiyama; Katsutaka Hashiba; Miki Shimizu; Klaus Ebnet; Shigeo Ohno
Journal:  J Cell Sci       Date:  2002-09-15       Impact factor: 5.285

5.  Increased endothelial monolayer permeability is induced by serum from women with preeclampsia but not by serum from women with normal pregnancy or that are not pregnant.

Authors:  Yanping Zhang; Yang Gu; Hui Li; Michael J Lucas; Yuping Wang
Journal:  Hypertens Pregnancy       Date:  2003       Impact factor: 2.108

6.  Placental trophoblast-derived factors diminish endothelial barrier function.

Authors:  Yuping Wang; David F Lewis; Yang Gu; Yanping Zhang; J Steve Alexander; D Neil Granger
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

7.  Altered subcellular distribution of cadherin-5 in endothelial cells caused by the serum of pre-eclamptic patients.

Authors:  T Groten; R Kreienberg; I Fialka; L Huber; D Wedlich
Journal:  Mol Hum Reprod       Date:  2000-11       Impact factor: 4.025

8.  Endothelial junctional protein redistribution and increased monolayer permeability in human umbilical vein endothelial cells isolated during preeclampsia.

Authors:  Yuping Wang; Yang Gu; D Neil Granger; James M Roberts; J Steven Alexander
Journal:  Am J Obstet Gynecol       Date:  2002-02       Impact factor: 8.661

9.  Atypical protein kinase C is involved in the evolutionarily conserved par protein complex and plays a critical role in establishing epithelia-specific junctional structures.

Authors:  A Suzuki; T Yamanaka; T Hirose; N Manabe; K Mizuno; M Shimizu; K Akimoto; Y Izumi; T Ohnishi; S Ohno
Journal:  J Cell Biol       Date:  2001-03-19       Impact factor: 10.539

10.  Atypical protein kinase C (PKCzeta/lambda) is a convergent downstream target of the insulin-stimulated phosphatidylinositol 3-kinase and TC10 signaling pathways.

Authors:  Makoto Kanzaki; Silvia Mora; Joseph B Hwang; Alan R Saltiel; Jeffrey E Pessin
Journal:  J Cell Biol       Date:  2004-01-19       Impact factor: 10.539

View more
  3 in total

Review 1.  The Involvement of Cell Adhesion Molecules, Tight Junctions, and Gap Junctions in Human Placentation.

Authors:  Enoch Appiah Adu-Gyamfi; Armin Czika; Philip Narteh Gorleku; Amin Ullah; Zulqarnain Panhwar; Ling-Ling Ruan; Yu-Bin Ding; Ying-Xiong Wang
Journal:  Reprod Sci       Date:  2020-11-04       Impact factor: 3.060

2.  PAR-2 triggers placenta-derived protease-induced altered VE-cadherin reorganization at endothelial junctions in preeclampsia.

Authors:  Y Gu; L J Groome; J S Alexander; Y Wang
Journal:  Placenta       Date:  2012-07-26       Impact factor: 3.481

3.  Genome-Wide Mapping of 5mC and 5hmC Identified Differentially Modified Genomic Regions in Late-Onset Severe Preeclampsia: A Pilot Study.

Authors:  Lisha Zhu; Ruitu Lv; Lingchun Kong; Haidong Cheng; Fei Lan; Xiaotian Li
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.